Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

FDA approves Verastem's duvelisib

September 24, 2018 10:21 PM UTC

FDA approved Copiktra duvelisib from Verastem Inc. (NASDAQ:VSTM) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. The agency also granted accelerated approval to the drug for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The approvals came ahead of the application's Oct. 5 PDUFA date.

Verastem plans to launch Copiktra in the U.S. immediately. The drug will have a monthly list price of $11,800, Chief Commercial Officer Joseph Lobacki said on a conference call Monday...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article